Log in to save to my catalogue

Serum CD73 is a prognostic factor in patients with metastatic melanoma and is associated with respon...

Serum CD73 is a prognostic factor in patients with metastatic melanoma and is associated with respon...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_ca411bc46b9f4db2a7c3cf284f8adfd0

Serum CD73 is a prognostic factor in patients with metastatic melanoma and is associated with response to anti-PD-1 therapy

About this item

Full title

Serum CD73 is a prognostic factor in patients with metastatic melanoma and is associated with response to anti-PD-1 therapy

Publisher

England: BMJ Publishing Group Ltd

Journal title

Journal for immunotherapy of cancer, 2020-12, Vol.8 (2), p.e001689

Language

English

Formats

Publication information

Publisher

England: BMJ Publishing Group Ltd

More information

Scope and Contents

Contents

BackgroundInhibitors of immune checkpoint programmed cell death protein 1 (PD-1) receptor on T cells have shown remarkable clinical outcomes in metastatic melanoma. However, most patients are resistant to therapy. Production of extracellular adenosine, via CD73-mediated catabolism of AMP, contributes to suppress T-cell-mediated responses against ca...

Alternative Titles

Full title

Serum CD73 is a prognostic factor in patients with metastatic melanoma and is associated with response to anti-PD-1 therapy

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_ca411bc46b9f4db2a7c3cf284f8adfd0

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_ca411bc46b9f4db2a7c3cf284f8adfd0

Other Identifiers

ISSN

2051-1426

E-ISSN

2051-1426

DOI

10.1136/jitc-2020-001689

How to access this item